CXCR4 is the major co-receptor used by X4 strains of human immunodeficiency virus type I (HIV-1). In HIV-1-infected patients, the appearance of X4 strains (T cell linetropic) correlates with disease progression. Since its discovery, the CXCR4 co-receptor has been a major target for different agents which block its function, such as stromalderived factor 1␣ (SDF-1␣) and the anti-CXCR4 monoclonal antibody, 12G5. In the present studies, the 12G5 hybridoma was used to construct a single-chain variable antibody fragment (SFv). Murine leukemia virus (MLV) and simian virus 40 (SV 40 ) were utilized as delivery vehicles for the anti-CXCR4 SFv. Intracellular expression of the anti-CXCR4 SFv led to down-regulation of this critical co-receptor, as demon-
Introduction
CD4 has long been identified as a receptor for HIV-1. The HIV-1 envelope binds to the cell surface via a strong interaction with the CD4 receptor. It is now known that this interaction is not sufficient to initiate viral:cell membrane fusion, nor to establish a productive infection. 1 Based on these data, the search for viral co-receptors has proceeded and it required 10 years until Berger and colleagues identified the first HIV-1 co-receptor. Initially, this moiety was entitled fusin, which when co-expressed with CD4 on murine NIH 3T3 cells allowed fusion with cells bearing HIV-1 envelope proteins. 2 The co-receptor is a seven-transmembrane domain glycoprotein of the chemokine super family of receptors. 2 Fusin was subsequently renamed CXC-chemokine receptor 4 (CXCR4), and acts as the co-receptor for T cell line-tropic isolates of HIV-1. Later, a number of groups simultaneously reported that the chemokine receptor, CCR5, was the required second receptor for entry of macrophage-tropic isolates of HIV-1. [3] [4] [5] [6] [7] [8] Following discovery of these co-receptors, the nomenclature of HIV-1 tropism was changed to reflect strated by immunostaining. This effect significantly and specifically protected transduced cells from challenge with HIV-1, as measured by HIV-1 p24 antigen expression. Inhibition of HIV-1 replication was specific for X4 HIV-1 strains as demonstrated by MAGI assays. HeLa-CD4/␤gal-CCR5 cells expressing the anti-CXCR4 SFv showed significant inhibition of infectivity by the X4 HIV-1 strain NL4-3, but not with the R5 HIV-1 strain Bal. Thus, this anti-HIV-1 molecular therapy has the potential to inhibit HIV-1 replication and virion spread. Targeting CXCR4 by intracellular immunization could be of additional benefit to certain HIV-1-infected patients on highly active antiretroviral therapy (HAART). Gene Therapy (2001) 8, 408-418. the phenotypic diversity conferred by co-receptor specificity. T cell line-tropic HIV-1 strains are now called 'X4 tropic', and macrophage (M)-tropic HIV-1 strains are now called 'R5 tropic', while dual-tropic strains are termed 'X4-R5 tropic'. 9 Scarlatti and colleagues 10 showed a consistent pattern of evolution of viral co-receptor usage and sensitivity to chemokine-mediated suppression in a longitudinal follow-up of children with progressive HIV-1 infection. Viral isolates obtained during asymptomatic stages generally were R5-tropic. By contrast, the majority of the isolates derived after progression of the disease were X4-tropic. 10 It has been reported that the viral isolates derived from the transition of HIV-1-infected non-progressors to progressors are R5-X4 dual-tropic. 11 Recently, it has been shown that the X4 phenotype of recombinant HIV-1 strains and primary HIV-1 isolates is linked to a highly pathogenic phenotype in ex vivo lymphoid tissues, which is substantially inhibited by interfering with CXCR4-mediated entry. 12 The same group reported that the specificity of recombinant HIV-1 strains tropic for CXCR4 promote potent depletion of CD4 + T lymphocytes in human lymphoid histocultures. 13 With the identification of CCR5 and CXCR4 as cofactors for HIV-1 entry into macrophages and CD4
+ T lymphocytes, investigators have sought to inhibit or block interactions between the HIV-1 envelope and chemokine co-receptors. One of the major problems in designing anti-chemokine therapeutic agents are the complexities of chemokine receptor-ligand(s) interactions. This represents the blocking of a tri-complex, gp120-CD4-CXCR4. The natural ligand of CXCR4 was identified as stromal cell-derived cofactor (SDF-1), an ␣ chemokine. SDF-1 ␣ blocks the infection of T cells with X4 strains of HIV-1.
14,15 Thus, gene therapy constructs that downregulate or inactivate CXCR4 may have therapeutic value. The first monoclonal antibody to CXCR4 (12G5) was described and showed that this antibody blocked cellular infection with X4 strains of HIV-1. 16 Subsequently, the 12G5 epitope was mapped to the third extracellular domain of CXCR4, e3, and detects a conformational epitope. 16, 17 In the present studies, we have utilized gene transfer systems based on Moloney murine leukemia virus (MLV) and simian virus-40 (SV 40 ) as vectors.
18 SV 40 infects a wide range of cell types from humans and other mammals, and expresses its genes in these cells. Recombinant, replication-deficient SV 40 -derived vectors may express transgenes stably in cell lines, in primary cultures, and in vivo. [18] [19] [20] We have reported that intracellular expression of SFv moieties targeted to HIV-1 proteins, including reverse transcriptase (RT), integrase (IN), and Rev, inhibited HIV-1 replication in human cells. [21] [22] [23] [24] To assess further intracellular immunization as a tool for gene therapy of HIV-1 infection, a cellular protein, CXCR4, rather than a viral-specific protein was targeted for selective blockade by an anti-CXCR4 intracellular SFv expression construct, delivered using the MLV and SV 40 vectors. The effectiveness of these constructs in inhibiting HIV-1 was analyzed.
In these present studies, it is demonstrated that MLV and SV 40 -derived vectors deliver anti-CXCR4 SFv to selected and unselected human T lymphocytic cells, respectively. Anti-CXCR4SFv expression strongly inhibits HIV-1 replication, as measured by HIV-1 p24 antigen expression and syncytia formation, via down-regulating the CXCR4 co-receptor.
Results
Cloning of the anti-CXCR4 SFv in murine retroviral and SV 40 
expression vectors
The MLV retroviral and SV 40 vector plasmids used in all the experiments are illustrated in Figure 1 . The sequences encoding the variable light (V L ) and variable heavy (V H ) chains of the anti-CXCR4 monoclonal antibody (Mab) were cloned from mRNA of the 12G5 murine hybridoma cell line. After ligation of V L and V H chains into a single fragment, by utilizing the flexible linker (GGGGS) 3 , the SFv fragment was cloned into a MLV-based retroviral expression vector, the pSLXCMV, downstream of an internal cytomegalovirus (CMV) promoter, to obtain the pSLXCMV-CXCR4 SFv construct (Figure 1b) . The nucleotide and the amino acid sequence of the anti-CXCR4 SFv clone are shown in Figure 1a . After analyzing the sequence in GenBank, we found that the V H region appeared to be encoded by the T15 family member. The V H T15 segment of the anti-CXCR4 SFv had seven nucleotide differences compared with the most homologous matched consensus sequence. 25 These differences in nucleotides led to five changes in the amino acid sequence. The J H region is derived from J H 3. The J H 3 segGene Therapy ment of the anti-CXCR4 SFv had two nucleotide differences, as compared with the consensus sequence which led to two amino acid changes. 26 Since the CDR3 region of the heavy chain is a highly variable region, it was difficult to match this region with a consensus sequence. The V chain nucleotide and deduced amino acid sequences are represented in Figure 1a , and were assigned to the V-8 group and had a homology of 97% with the consensus sequence. 27 The V-8 segment of the anti-CXCR4 SFv had nine nucleotide differences compared with the consensus sequence, which led to three changes in the amino acid sequence. 27 Analysis of the J segment showed that the anti-CXCR4 SFv used J-1. 26 No nucleotide changes were found for J-1. All the amino acids and nucleotides changes are in bold, as shown in Figure 1a .
The pSLXCMV-VPR-CAT plasmid was used as a negative control, and the construct has been described previously. 22 A map of the SV(HBS) construct has been reported. 28 The anti-CXCR4 SFv fragment was also cloned into an SV 40 expression vector downstream of the cytomegalovirus immediate-early promoter (CMV-IEP). The HA-11 tag was added at the C-terminus of the anti-CXCR4 SFv cDNA. A map of the SV40 vector containing the anti-CXCR4 SFv driven by CMV-IEP, and used for all the present studies, is shown in Figure 1c . The orientations and structures of open reading frames for all the plasmids were verified by DNA sequencing.
Expression of the CXCR4 SFv protein in mammalian cells
To obtain transfectants expressing the anti-CXCR4 SFv protein, helper-free recombinant MLV-based retroviruses were produced by transfection of PG13 packaging cells with recombinant retrovirus vector plasmids. PG13 cells were transfected with the plasmid DNA (pSLXCMV-CXCR4 SFv) by a standard calcium-phosphate method. After 2 weeks of selection in G418, the cells were subjected to immunostaining. The expression of the protein was detected by using a goat polyclonal anti-mouse IgG. As shown in Figure 2 , the transfected PG13 cells stably express the anti-CXCR4 SFv. PG13 cells stably expressing the Vpr-CAT protein were used as a control ( Figure 2 ). As illustrated, these proteins demonstrated strong cytoplasmic signals.
To obtain transfectants expressing anti-CXCR4 SFv and HBsAg, recombinant SV 40 -based viruses were also prepared from COS-7 packaging cells, as described in Materials and methods. After infection with SV(CXCR4 SFv) or SV(HBS), the cells were cultured without selection and then analyzed by Western blotting. Lysates were prepared from 10 6 COS-7 cells transduced, as described, with SV(CXCR4 SFv), SV(HBS), or mock-transduced. These proteins were electrophoresed using SDS-PAGE, blotted to PVDF membranes, probed with the anti-HA11 IgG antibody, and visualized as described in Materials and methods. These studies demonstrated that unselected SV(CXCR4 SFv)-transduced cells expressed the anti-CXCR4 SFv transgene ( Figure 2D ), as compared with the controls.
Inhibition of HIV-1 replication in human T lymphoid cells that express the anti-CXCR4 SFv: comparative effects of MLV and SV 40 vector transductions It was then analyzed whether intracellular expression of anti-CXCR4 SFv delivered by MLV or SV 40 into SupT1 (Figure 3a ). Based on our previous studies, challenges were performed at a viral input, which leads to relatively high levels of viral growth in these T cells (ie nanograms, rather than picograms, per milliliter of HIV-1 p24 antigen expression) by 24 days after infection of control cells. Replication of HIV-1 in these cultures was It was next determined whether intracellular expression of anti-CXCR4 SFv delivered by SV 40 into unselected SupT1 cells could prevent HIV-1 replication. Significant protection was observed in SupT1 cells expressing anti-CXCR4 SFv delivered by SV 40 without selection ( Figure 3b ). These data indicate virtually complete protection from HIV-1 by SV 40 transduction of anti-CXCR4 SFv in unselected cells, comparable to the levels of protection achieved using the same anti-CXCR4-SFv
Gene Therapy delivered with MLV-CXCR4 SFv into cells which were then selected.
Control nontransduced cells showed wild-type HIV-1 replication, as demonstrated by dramatic initial increases in HIV-1 p24 antigen (Figure 3b ). On day 33 after infection, SupT1 CXCR4 SFv mixed cell populations showed complete inhibition of HIV-1 p24 antigen production, as compared with the nontransduced SupT1. At higher viral inputs, little or no complete protection from HIV-1 challenge was observed in cultures expressing anti-CXCR4 SFv, transduced by either MLV or SV 40 . Of note, delays of viral out-growth were noted at higher viral inputs (not illustrated), but Figure 3a and 3b are utilized to illustrate complete suppression of viral replication for over a month in culture.
Down-modulation of CXCR4 receptor in cells expressing anti-CXCR4 SFv
To determine the effects of anti-CXCR4 SFv on the surface expression of the CXCR4 receptor, SupT1 cells were used. As described above SupT1 cells were co-cultured with the PG13 cells expressing anti-CXCR4 SFv and fol- 1, 2) . lowed by G418 selection. Expression of the anti-CXCR4 SFv in SupT1 cells was verified by immunostaining, as described above (data not shown). As controls, the stably expressing SupT1-anti IN#33 SFv was used. The IN#33 SFv binds to the nonspecific DNA binding site in HIV-1 IN, and inhibits HIV-1 replication in transduced human T lymphocytic cells. 24 The expression of the CXCR4 receptor in SupT1 cells was confirmed by immunostaining using 12G5 anti-CXCR4 monoclonal antibody (Figure 4 ). SupT1 cells expressing the anti-CXCR4 SFv showed a dramatic decrease of the surface expression of the CXCR4 receptor. Of importance, the SupT1 cells controls expressing IN#33SFv showed normal surface expression of the CXCR4 receptor. To ascertain that the anti-CXCR4 SFv indeed down-modulated the CXCR4 receptor and that this was not a masking effect since the anti-CXCR4 SFv was made from the 12G5 hybridoma, we utilized another anti-CXCR4 monoclonal antibody, MAB171, which binds to a different epitope to assay CXCR4 by immunostaining. SupT1 cells stably expressing the anti-CXCR4 SFv showed little or no surface expression of CXCR4 when using either 12G5 or MAB171 antibodies ( Figure 5A and E), as compared with the controls (Figure 5C and G). The down-modulation of the surface expression of CXCR4 was also detected by flow cytometry in SupT1 cells transduced with SV40 expressing the anti-CXCR4 SFv (not illustrated).
Figure 2 Analysis of anti-CXCR4 SFv protein expression in cells. Stably transfected PG13 cells were fixed and immunostained with goat antimouse anti-kappa, using fluorescein isothiocyanate (FITC)-conjugated rabbit anti-goat IgG (see Materials and methods). PG13 cells transduced with pSLXCMV-CXCR4 SFv demonstrated mainly cytoplasmic staining (A). PG13 cells transduced with pSLXCMV-Vpr-CAT (B, C) were used as controls. These photomicrographs are representative of two independent experiments. (C) A phase contrast image of (B)
.
Figure 3 Inhibition of HIV-1 replication in anti-CXCR4 SFv-transduced T lymphoid cells. (a) SupT1 cells were transduced with Vpr-CAT and anti-CXCR4 SFv retroviral expression vectors (mixed cellular populations). Stably transfected SupT1 cells were infected with HIV-1 NL4-3 (0.05 pg p24 antigen equivalents). (b) SupT1 cells were transduced with SV-CXCR4 SFv three times, as described in
Anti-CXCR4 SFv reduces the infectivity of X4 HIV-1 strains In order to determine whether the effects of HIV-1 inhibition by the anti-CXCR4 SFv was specific to X4 HIV-1 strains, the MAGI cell assay was utilized. In this assay, HeLa cells carrying both CXCR4 and CCR5, also contain the ␤-galactosidase (␤-gal) gene under the control of the HIV-1 LTR. In allowing visualization of ␤-gal-expressing cells, the assay reflects the ability of HIV-1 to infect, integrate, and express the viral transactivator, Tat. After 48 h of infection, the HeLa/CCR5/ CD4-LTR/␤-gal cells were fixed and stained with X-gal and the number of ␤-galexpressing syncytia cells was counted. HeLa/CCR5/ CD4-LTR/␤-gal cells were transduced with SV 40 expressing HBsAg as a control or anti-CXCR4 SFv three times, as described in the Materials and methods. In this study, Gene Therapy only rSV 40 delivery of anti-CXCR4 SFv was used because rSV 40 gene delivery is effective without selection, and the required Neo R expression to select for MuLV anti-CXCR4 SFv was already active in the MAGI cells. The cells were then infected with the equivalent amounts of HIV-1 (p24 antigen equivalents) of input viruses (NL4-3 and Bal). As shown in Figure 6 , cells expressing anti-CXCR4 SFv were significantly less infected, by at least 50%, compared with the cells expressing HBsAg, utilizing the X4 HIV-1 NL4-3. The decrease in the number of positive syncytia was more robust when cells were infected at a lower viral input (data not illustrated). By contrast, no antiviral effect was observed when cells were infected with an R5 HIV-1, Bal. These results, which measure viral infectivity, strongly support the viral production and expression data obtained with SupT1 cells (Figures 3, 4 and 5) . The reduction of viral replication is most likely due to specific effects on the viral entry process. Taken together, these results indicate that anti-CXCR4 SFv: (1) can specifically decrease the susceptibility of the cells to infection by X4 HIV-1 strains; (2) this antiretroviral effect is secondary to the down-regulation of the CXCR4 receptor.
Discussion
In these studies, it was demonstrated that intracellular expression of an anti-CXCR4 SFv could protect cells from infection with CXCR4-utilizing strains of HIV-1. MLV and SV 40 vectors were utilized to deliver the anti-CXCR4 SFv. We reported previously that using both vectors to deliver anti-HIV-1 molecular therapeutics agents, HIV-1 infection could be inhibited in human T cells. 22 It was shown that SV 40 as a transduction vehicle is equally effective as MLV SFvIN#33 in protecting SupT1 cells from HIV-1 infection, and that the SV 40 delivery system had the distinct advantage in that its utility does not require selection for transgene-expressing cells before challenge with HIV-1. 21 The present studies now extend the use of SV 40 and MLV, to deliver anti-CXCR4 SFv, and show that the anti-CXCR4 SFv is quite effective in inhibiting HIV-1 replication in T lymphocytic cells and HeLa/R5 cells.
Other approaches are being used to target CXCR4 using different inhibitors. Peptides, small molecule antagonists of CXCR4, antisense CXCR4 mRNA, and Nterminal-truncated forms of SDF-1 have been shown to
Figure 5 Down-regulation of the surface expression of CXCR4. Stably transfected SupT1 cells were fixed and immunostained with either mouse anti-CXCR4 monoclonal antibody, 12G5, or MAB 171, using fluorescein isothiocyanate (Cy2)-conjugated rabbit anti-mouse IgG at 4°C (see Materials and methods). SupT1 cells transduced with pSLXCMV-CXCR4 SFv (A, E) demonstrated no staining at the surface. SupT1 cells transduced with pSLXCMV-SFvIN#33 (C, G) were used as controls, and demonstrated strong signals for CXCR4 receptor expression. (B, D, F and H) are the phase contrasts of (A, C, E and F), respectively. These photomicrographs are representative of two independent experiments. Original magnification ×40.
inhibit HIV-1 replication. [29] [30] [31] [32] [33] An SDF intrakine, carrying an endoplasmic reticulum (ER) localization signal (KDEL), demonstrated an inhibitory effect in lymphocytes for infection by HIV-1. 34 This SDF intrakine effectively blocked the cell surface expression of CXCR4 on human lymphocytes. In another study, the activities of two forms of SDF-1 were examined: SDF-1␣, beginning with the amino-terminal amino acid lysine, and Met-SDF-1␣, which had an added N-terminal methionine. 35 The authors showed that these two moieties were potent inhibitors of X4-tropic HIV-1 infection. The inhibition of HIV-1 infection also correlated with down-modulation of cell surface expression of CXCR4 by these agents. 35 The 12G5 monoclonal antibody has been shown to block infection of X4-tropic HIV-1, when utilized extracellularly. 16 This antibody is very well-characterized and commonly used to study CXCR4 function. Using this monoclonal antibody as a starting point, the present
Figure 6 Effect of anti-CXCR4 SFv expression on viral infectivity in HeLaCD4/CCR5/LTR/␤-gal cells. HeLa-CD4/CCR5/LTR/␤-gal cells were treated with SV-CXCR4 SFv or SV-HBS three times. The cells (mixed cellular populations) were infected with either X4-tropic HIV-1 NL4-3 or R5-tropic HIV-1 Bal at the same quantities of HIV-1 p24 antigen equivalents (50 pg of p24 antigen). Infectivity was assayed by transactivation of the endogenous LTR/␤-gal gene, as described in the Materials and methods section. Histograms represent the numbers of X-gal-positive syncytia. The data are representative examples of two independent experiments. N, NL4-3; B, Bal.
results showed that the intracellularly expressed anti-CXCR4 (12G5) SFv demonstrated a robust anti-HIV-1 effect. In addition, it was demonstrated that the inhibition was limited to X4-tropic HIV-1 infection (Figure 6 ), showing the specificity of this effect. As was demonstrated in other studies that utilized different anti-CXCR4 strategies, anti-CXCR4 SFv could also down-regulate the surface expression of CXCR4. Taken together, it appears that down-modulation of the surface expression of CXCR4 may be the crucial aspect of the inhibition of X4-tropic HIV-1 infection by several anti-CXCR4 approaches.
Other methods aim to prevent viral entry by targeting the CCR5 co-receptor. Intracellular expression of an anti-CCR5 with an ER-retention signal blocked surface expression of CCR5. The authors demonstrated that the CCR5 + T cell line, PM1, which express the anti-CCR5-ER could be protected from infection with an R5 tropic HIV-1 strain. 36 In another study, an anti-CCR5 ribozyme also showed an anti-HIV-1 effect. The authors transduced CD34 + cells with the anti-CCR5 ribozyme using a retroviral vector. Differentiated progeny macrophages expressing the ribozyme showed resistance to HIV-1 infection. Also, the authors showed that the anti-CCR5 ribozyme down-regulated the surface expression of CCR5 in HOS-R5 cells. 37 In the present experiments, transduction efficiency was higher using SV 40 without selection, than with MLV which required selection using G418. For instance, MLV could not be used to deliver any gene to perform the studies in HeLa/R5 cells. These cells required culture in the presence of three selection agents (G418, hygromycin and puromycin), which made the use of the neo R -carrying MLV vector impossible. Using SV 40 , by transducing the cells three times, transduction percentages close to 80% were achieved. This is an advantage that could be very useful for transduction of primary cells. It has been reported that SV 40 can infect such primary cells as hematopoietic and peripheral blood mononuclear cells (PBMC). 20, 38, 39 We have also found high-efficiency gene transfer to bone marrow-derived cells using SV 40 , as described. 40 This is of importance, as non-activated T lymphocytes and non-proliferating monocyte/macrophages are critical cellular reservoirs for HIV-1 in vivo.
Of note, most if not all anti-HIV-1 gene therapeutics can be overwhelmed by utilizing relatively high challenge viral inputs in vitro. This observation was repeated in our studies: anti-CXCR4 SFv delivered by both SV 40 and MLV was highly effective in inhibiting HIV-1 at certain viral inputs, but did not dramatically alter the course of HIV-1 infection at high challenge viral doses. Thus, the approach described here may not inhibit HIV-1 transfer in the interstices of lymphatic tissues of infected individuals, where HIV-1 concentrations may be higher than those inhibited by the therapeutic approaches described by most gene therapeutic approaches. 41 In such cases, multiple simultaneous therapeutic modalities or multiple administrations may be necessary to provide effective protection.
Targeting the entry of the virus by blocking the coreceptor CXCR4 represents a potential complementary therapeutic approach for certain HIV-1-infected patients on highly active antiretroviral therapy (HAART). Of note, the present studies demonstrate that, in addition to virally encoded proteins, SFvs can also be targeted to relevant cellular proteins involved in lentiviral production. The ability to deliver functional anti-HIV-1 genes using SV 40 as vector represents a novel and potentially useful technology that could contribute to the efficient inhibition of HIV-1 replication. The high efficiency of SV 40 transduction, the lack of need for cell selection, the ability of SV 40 to transduce a wide range of target cells, and the potential for multiple administrations in vivo, suggest that SV 40 -delivered antiretroviral gene therapy represents a potentially useful new class of antiretroviral delivery vehicles. These approaches could also be useful in understanding the biology of CXCR4 and in studying the molecular events within the lentiviral life-cycle. Further studies will be conducted in severe combined immunodeficiency human (SCID hu ) mice to develop an in vivo model of the anti-CXCR4 SFv's effects on HIV-1 replication. These studies will also address the question of whether a switch in viral tropism to a CCR5 phenotype may occur with this antilentiviral approach.
Materials and methods

Plasmids and viral expression constructs
The HIV-1 molecular clones used in this study were pNL 4-3 and pBal. These strains were obtained from the AIDS Reagent Repository (NIH). HIV-1 NL4-3 is a T cell line-tropic (CXCR4) viral strain with highly cytopathic effects and Bal is an M-tropic (CCR5) viral strain.
Gene Therapy
The 12G5 hybridoma cell line used in these studies, which produces a monoclonal antibody (MAb) against the CXCR4 protein, has been described previously. 16 The hybridoma cells were grown in RPMI-1640 medium and 10% fetal calf serum (FCS). Approximately 2 × 10 7 cells were used for preparation of total cellular RNA by lysis with guanidium isothiocyanate buffer and a cesium chloride gradient procedure, as described previously. 42 The cDNAs of the variable heavy chain (V H ) and light chain (V L ) regions of anti-CXCR4 monoclonal IgG transcripts were synthesized by reverse transcriptaseinitiated polymerase chain reaction (RT-PCR). Primer sets used to amplify murine variable-region heavy and light chains were obtained from Novagen (Ig-Primer Methodology; Madison, WI, USA). For first-strand cDNA synthesis, 5 g of total RNA was mixed with the 3Ј primers (antisense) specific for V L and V H regions, heated for 5 min at 65°C, and then incubated at 37°C for 1 h with 200 U of avian myeloblastosis virus RT in a buffer containing 0.07 m KCl, 0.02 m Tris (pH 8.3), 5 mm dithiothreitol, and 1.0 m (each) deoxynucleoside triphosphates (dNTP) in 10 m volume. After reverse transcription, 5 m of template cDNA was subjected to PCR amplification, using the appropriate primers (Novagen) along with 0.5 m of Taq polymerase (Perkin-Elmer Corporation, Norfolk, CT, USA) in PCR buffer containing 2.5 mm MgCl 2 in a 50 l total volume. Amplification was carried out in a thermal cycler (Perkin-Elmer Corporation) for one cycle of denaturation at 94°C for 5 min and then for 35 cycles with the following parameters: denaturation for 1 min at 94°C, annealing for 90 s at 50°C, and extension for 60 s at 72°C, with a final extension of 10 min. Each of the PCR-amplified fragments were cloned into the pT7 Blue (R) vector (Novagen). Clones were first screened by PCR amplification, using primers specific to the pT7 polylinker for the correct size, and analyzed further by DNA sequencing. PCR primers (5Ј and 3Ј ends), containing appropriate restriction enzyme sites for further cloning, were used to reamplify each of the V L and V H fragments, with deletion of the remaining secretory leader sequences. The DNAs of light and heavy chains were joined together via a flexible linker, as described previously. 24 The anti-CXCR4 V L fragment (348 bp) was cloned via NdeI and ApaI sites 5Ј to the linker, and the anti-CXCR4 V H fragment (408 bp) was cloned via SacI and BamHI sites 3Ј to the linker, to obtain anti-CXCR4 SFV as a single gene construct. The anti-CXCR4 SFv construct, containing a Flag tag was subcloned as an MluI-BamHI fragment in the MluI-BglII sites of the polylinker region of the amphotropic MLVvector pSLXCMV. The nucleotide sequence for Flag is GAC TAC AAG GAC GAC GAT GAC AAG. Accurate cloning of the DNA of the SFv in the vector was confirmed by DNA sequencing. The construct, pSLXCMV-Vpr-CAT, which was used as control, has been described previously. 22 Briefly, pSLXCMV-Vpr-CAT was constructed by inserting a 304 bp BamHI-MluI fragment, containing the Vpr gene, via BamHI-MluI sites of the polylinker region of the amphotropic MLV vector, pSLXCMV. The stop codon of the Vpr gene was removed and replaced by a MluI site, to permit fusion of the 677 bp MluI-BamHI fragment, containing the chloramphenicol acetyl transferase (CAT) gene, into pSLXCMVVpr* in MluI-BglII sites. 22 The construct, MLV vector containing anti-IN#33 (pSLXCMV-SFvIN#33) was described previously. 24 The IN#33 SFv binds to the nonspecific DNA binding site in HIV-1 integrase (IN), and directly inhibits HIV-1 replication in transduced human T lymphocytic cells. 21 Construction of recombinant SV 40 derivative viruses for gene transfer has been described previously. 18 The recombinant SV 40 -derived virus, SV-CXCR4-SFV was made similarly and will be described briefly. The large T antigen gene was excised from the cloned wild-type SV 40 genome (pBSV-1, a kind gift of Janet S Butel, Baylor College of Medicine, Houston, TX, USA) and replaced by a polylinker. An expression construct containing the cytomegalovirus intermediate-early promoter (CMV-IEP) plus the cDNA for anti-CXCR4-SFv containing a hemagglutinin (HA)-11 tag was cloned into the polylinker, to yield pBSV(CMV) CXCR4-SFv. The nucleotide sequence for HA-11 is TAT CCT TAC GAT GTA CCA GAC TAT GCG.
The control virus used for certain SV 40 studies was SV(HBS). The production and characterization of this virus have been reported. 28 Briefly, the gene for hepatitis B surface antigen (HBsAg) was cloned into the Tagdeleted SV 40 genome, immediately downstream from two tandem SV 40 early promoters. The resulting plasmid was entitled pSV5(HBS).
Cell cultures
The PG13 amphototropic-retrovirus-packaging cell line and COS-7 SV 40 -packaging cell line were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS). The same culture conditions were used for 293T cells and HeLa-CD4-CCR5-LTR/␤gal cells (AIDS Reagent Repository, NIH, Bethesda, MD, USA). SupT1, a CD4 + human T lymphocyte cell line, susceptible to HIV-1 infection, was grown in RPMI-1640 medium and 10% FCS. All the cells were grown at 37°C in a humidified incubator with 5% CO 2 .
Production of amphotrophic retroviruses
Helper-free recombinant MLV-based retroviruses were produced by transfection of PG13 packaging cells with recombinant retrovirus vector plasmids. PG13 cells were transfected with 20 g of the plasmid DNA (pSLXCMV-CXCR4 SFv, pSLXCMV-SFvIN#33 or pSLXCMV-Vpr-CAT) by a standard calcium-phosphate method, and then incubated in DMEM containing 10% FCS (growth medium) for 14 h. This medium was then removed and replaced with fresh DMEM growth medium. After a 24 h incubation, cells were replated in DMEM growth medium containing G418 (800 g/ml; Sigma, St Louis, MO, USA). The medium was changed every 3-4 days until colonies formed. The G418-resistant colonies were then pooled and grown for 2 more weeks in medium containing G418.
Production of SV 40 derivative viruses
The techniques used in generating viruses from plasmids, such as pSV5(HBS) and pBSV(CMV) CXCR4-SFv, have been described. 18 Briefly, the virus genome was excised from the carrier plasmid and purified by agarose gel electrophoresis. It was then recircularized and transfected into COS-7 cells, the packaging cell line used for these studies. No helper virus was used as COS cells supply the necessary T antigen in trans. These virus stocks were prepared as cell lysates. After initial virus preparations were created in this fashion, viral stocks were expanded by infecting COS-7 cells with virus from the original preparation. Further transfections were not performed. Resulting viruses were replication incompetent. 18 Virus stocks are titered by in situ PCR, as described previously. 43 This provides for direct enumeration of infectious units in a preparation. Although very few positive cells may represent replication-defective virus after entry and integration, nevertheless, this procedure correlates with SV40 vector-transduced transgene expression in target cells. 43 HIV-1 viral stocks 293T cells were transfected by a standard calcium-phosphate method (Promega, Madison, WI, USA). 293T cells (1 × 10 6 ) were plated in 10-cm dishes, transfected with 10 g of pNL 4-3 DNA and then incubated in DMEM containing 10% FCS (growth medium) for 7 h. The medium was then removed and replaced with fresh DMEM growth medium and 10% FCS. Virus-containing supernatants were collected at 48 h. The quantity of virus present in transfected cell supernatants was determined by measuring HIV-1 p24 antigen levels, using an enzyme-linked immunosorbent assay (ELISA) (ZeptoMetrix Corporation, Buffalo, NY, USA).
Transduction of T lymphocytic cells
Procedures for infecting SupT1 cells with MLV-CXCR4-SFv, and for selecting transgene-expressing transduced cells, have been reported elsewhere in detail. 43 Briefly, SupT1 cells were co-cultured with the stably transfected PG13 cells expressing Vpr-CAT, SFvIN#33, or anti-CXCR4 SFv constructs, to permit the most efficient transduction by the MLV virions produced by PG13 cells, for 48 h. SupT1 cells were then washed with serum-free medium and maintained under G418 selection conditions for 2 weeks. Each of the infected mixed cell populations was cultured in G418-containing medium (800 g/ml) for 2 weeks.
For transduction using SV 40 -derived vectors, SupT1 cells were treated with SV(CXCR4-SFv), carrying the cDNA for CXCR4-SFv for 24 h at a multiplicity of infection (MOI) of 10. This step was repeated twice, but at a MOI of 3, on sequential days. No selection of transduced cells was used. The SV 40 -transduced SupT1 cells were then cultured for 2 weeks.
HIV-1 challenge
The mixed populations of HIV-1-susceptible T cells (SupT1) which expressed the anti-CXCR4-SFv, and Vpr-CAT proteins were maintained in RPMI-1640 and 10% FCS for at least 2 weeks before HIV-1 infection. Parental SupT1 cells alone and cells expressing the anti-CXCR4-SFv, and Vpr-CAT proteins were incubated with infectious cell-free HIV-1 NL4-3 overnight. The cells were washed with pre-warmed, serum-free medium and then maintained in growth medium. Every 3 days, cells were split 1:2 to maintain a cell density of approximately 10 6 /ml and the culture supernatants were collected for HIV-1 p24 antigen analyses. The HIV-1 p24 antigen levels in supernatants were determined by ELISA. Cell viability was monitored by trypan blue exclusion.
Immunostaining for protein expression Localization of intracellularly expressed anti-CXCR4-SFv protein within the cells and the detection of CXCR4 receptor expression were determined by indirect immunofluorescence assays. Infected SupT1 cells were cultured after infection with SV 40 or MLV vectors on eight-chambered glass slides overnight. Cells were then fixed with methanol at room temperature for 10 min and blocked overnight with 1% phosphate-buffered saline/bovine serum albumin (PBS/BSA). The slides were treated overnight with a 1:200 dilution of goat antimouse polyclonal IgG (Nordic Immunology, Tilburg, The Netherlands) at room temperature, anti-CXCR4 12G5 IgG or MAB171 (R&D Systems, Minneapolis, MN, USA) for 1 h at 4°C, which does not allow intracellular but rather cell surface staining. After several washings, cells were incubated with a 1:200 dilution FluoroLink-Cy2-labeled rabbit anti-goat IgG (Jackson Immunoresearch, West Grove, PA, USA) for 1 h at 37°C or a 1:200 dilution FluoroLink-Cy2-labeled rabbit anti-mouse IgG for 1 h at 4°C (Jackson Immunoresearch). After washing five times in PBS, cells were mounted and analyzed by epiflurorescence microscopy. All photomicrographs were obtained at 200 ISO with exposure times of 1 min. Under these conditions, photo-bleaching was greatly reduced.
Detection of anti-CXCR4 SFv protein by Western blot analysis Cos-7 cells (10 6 ), which had been transduced with SV 40 vector carrying the anti-CXCR4 SFv expression construct, were lysed with a lysis buffer (100 mm Tris pH 8.0, 100 mm NaCl, 0.5% NP-40, 1 mm PMSF, 10 g/ml leupeptin, 2 g/ml aprotinin, 10 g/ml pepstatin). Protein lysate was loaded on a 12% SDS-polyacrylamide gel, electrophoresed and blotted to a PVDF membrane (Schleicher & Schuell, Keene, NH, USA). The membrane was blocked with 5% skim milk for 2 h, treated with mouse anti-HA11 IgG (Covance, Princeton, NJ, USA) overnight at 4°C, and then with horseradish peroxidase (HRP)-conjugated rabbit anti-mouse IgG antibody for 2 h at room temperature. Signal was detected using a chemiluminescence reagent (DuPont NEN).
Multinuclear activation of a galactosidase indicator (MAGI) cell infectivity assay HeLa-CD4-CCR5-LTR/␤-gal cells were first transduced with SV (CXCR4-SFv) or SV (HBS) and then infected in duplicate with different viral stocks, at precisely the same normalized levels of HIV-1 p24 antigen. This cell line contains an integrated construct consisting of the ␤-galactosidase gene (␤-gal) under the control of the HIV-1 long terminal repeat (LTR). The MAGI assay was carried out as described previously. 22 Briefly, the infection of cells was stopped at 48 h after infection by removing the culture medium. The infected cells were then fixed with a solution of 0.2% glutaraldehyde and 1% formaldehyde for 5 min at room temperature. After fixation, the cells were washed with PBS and stained with X-gal (5-bromo-4-chloro-3-indolyl-␤-d-galactopyranoside) for 2 h at 37°C. Infected cells, which correspond to blue syncytial cells, were counted under an Olympus CK2 microscope (Olympus, Melville, NY, USA).
